The relationship between KRAS gene mutations and HLA class I antigen downregulation in the metastasis of non-small cell lung cancer

Journal of International Medical Research

Volumn 41, Issue 5, 2013, Pages 1473-1483

  He, Xiao Peng ^a   Song, Fu Jie ^b   Liu, Xiang Yan ^a   Wang, Zhou ^a   Li, Xiang Xin ^c   Liu, Fan Ying ^a   Chen, Gang ^a   Jiang, Wen Peng ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b Beijing Coal General Hospital   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

HLA class I; Human leucocyte antigen class I; KRAS; metastasis; non small cell lung cancer; v Ki ras2 Kirsten rat sarcoma viral oncogene homologue gene

Indexed keywords

HLA ANTIGEN CLASS 1;

ADULT; AGED; ARTICLE; CANCER SURGERY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; LUNG RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; WEDGE RESECTION;

HLA CLASS I; HUMAN LEUCOCYTE ANTIGEN CLASS I; KRAS; METASTASIS; NON-SMALL CELL LUNG CANCER; V-KI-RAS2 KIRSTEN RAT SARCOMA VIRAL ONCOGENE HOMOLOGUE GENE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CODON; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LUNG; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84887299344     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060513489801     Document Type: Article

References (49)

1. Alberg AJ,Brock MV,Samet JM.Epidemiology of lung cancer: looking to the future.J Clin Oncol. 2005;23:3175-3185.
2. Jemal A,Siegel R,Xu J, et al.Cancer statistics, 2010.CA Cancer J Clin. 2010;60:277-300.
3. Reck M.What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?.Ann Oncol. 2012;23:viii28- viii34.
4. Lima JP,dos Santos LV,Sasse EC, et al.Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: a systematic review with meta-analysis.Eur J Cancer. 2009;45:601-607.
5. Zhang Z, Zhang Y, Feng H,et al.Is video-assisted thoracic surgery lobectomy better than thoracotomy for early-stage non-small-cell lung cancer? A systematic review and meta-analysis. Eur J Cardiothorac Surg. Epub ahead of print 30 January 2013. DOI: 10.1093/ejcts/ezt015.
6. Vandin F,Upfal E,Raphael BJ.De novo discovery of mutated driver pathways in cancer.Genome Res. 2012;22:375-385.
7. Wen J,Fu J,Zhang W, et al.Genetic and epigenetic changes in lung carcinoma and their clinical implications.Mod Pathol. 2011;24:932-943.
8. Dunn GP,Old LJ,Schreiber RD.The immunobiology of cancer immunosurveillance and immunoediting.Immunity. 2004;21:137-148.
9. Dunn GP,Bruce AT,Ikeda H, et al.Cancer immunoediting: from immunosurveillance to tumor escape.Nat Immunol. 2002;3:991-998.
10. Dunn GP,Old LJ,Schreiber RD.The three Es of cancer immunoediting.Annu Rev Immunol. 2004;22:329-360.
11. Finn OJ.Cancer vaccines: between the idea and the reality.Nat Rev Immunol. 2003;3:630-641.
12. Aptsiauri N,Cabrera T,Mendez R, et al.Role of altered expression of HLA class I molecules in cancer progression.Adv Exp Med Biol. 2007;601:123-131.
13. Korkolopoulou P,Kaklamanis L,Pezzella F, et al.Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer.Br J Cancer. 1996;73:148-153.
14. Kikuchi E,Yamazaki K,Torigoe T, et al.HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer.Cancer Sci. 2007;98:1424-1430.
15. Sette A,Chesnut R,Fikes J.HLA expression in cancer: implications for T cell-based immunotherapy.Immunogenetics. 2001;53:255-263.
16. Kranenburg O.The KRAS oncogene: past, present, and future.Biochim Biophys Acta. 2005;1756:81-82.
17. Rodenhuis S.Ras and human tumors.Semin Cancer Biol. 1992;3:241-247.
18. Huncharek M,Muscat J,Geschwind JF.K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases.Carcinogenesis. 1999;20:1507-1510.
19. Mascaux C,Iannino N,Martin B, et al.The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis.Br J Cancer. 2005;92:131-139.
20. Toyooka S,Tsukuda K,Ouchida M, et al.Detection of codon 61 point mutations of the K-ras gene in lung and colorectal cancers by enriched PCR.Oncol Rep. 2003;10:1455-1459.
21. Tsim S,O'Dowd CA,Milroy R, et al.Staging of non-small cell lung cancer (NSCLC): a review.Respir Med. 2010;104:1767-1774.
22. Liu C,Sun C,Huang H, et al.Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy.Cancer Res. 2003;63:2957-2964.
23. Ogino T,Shigyo H,Ishii H, et al.HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker.Cancer Res. 2006;66:9281-9289.
24. Chen CY,Shiesh SC,Wu SJ.Rapid detection of K-ras mutations in bile by peptide nucleic acid-mediated PCR clamping and melting curve analysis: comparison with restriction fragment length polymorphism analysis.Clin Chem. 2004;50:481-489.
25. Jemal A,Siegel R,Ward E, et al.Cancer statistics, 2008.CA Cancer J Clin. 2008;58:71-96.
26. Gao W,Liu L,Lu X, et al.Circulating microRNAs: possible prediction biomarkers for personalized therapy of non-small-cell lung carcinoma.Clin Lung Cancer. 2011;12:14-17.
27. Smith CB,Kelley AS,Meier DE.Evidence for new standard of care in non-small cell lung cancer patients.Semin Thorac Cardiovasc Surg. 2010;22:193-194.
28. Turner D.The human leucocyte antigen (HLA) system.Vox Sang. 2004;87:87-90.
29. Ramnath N,Tan D,Li Q, et al.Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival?.Cancer Immunol Immunother. 2006;55:891-899.
30. Baba T,Hanagiri T,Takenoyama M, et al.Identification of a lung cancer antigen evading CTL attack due to loss of human leukocyte antigen (HLA) class I expression.Cancer Sci. 2010;101:2115-2120.
31. Lin A,Zhang X,Ruan YY, et al.HLA-F expression is a prognostic factor in patients with non-small-cell lung cancer.Lung Cancer. 2011;74:504-509.
32. Bos JL.Ras oncogenes in human cancer: a review.Cancer Res. 1989;49:4682-4689.
33. Pearson G,Robinson F,Beers Gibson T, et al.Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions.Endocr Rev. 2001;22:153-183.
34. Coulombe P,Meloche S.Atypical mitogen-activated protein kinases: structure, regulation and functions.Biochim Biophys Acta. 2007;1773:1376-1387.
35. Molina JR,Adjei AA.The Ras/Raf/MAPK pathway.J Thorac Oncol. 2006;1:7-9.
36. Leicht DT,Balan V,Kaplun A, et al.Raf kinases: function, regulation and role in human cancer.Biochim Biophys Acta. 2007;1773:1196-1212.
37. Kranenburg O,Gebbink MF,Voest EE.Stimulation of angiogenesis by Ras proteins.Biochim Biophys Acta. 2004;1654:23-37.
38. Dreesen O,Brivanlou AH.Signaling pathways in cancer and embryonic stem cells.Stem Cell Rev. 2007;3:7-17.
39. Sebolt-Leopold JS,Herrera R.Targeting the mitogen-activated protein kinase cascade to treat cancer.Nat Rev Cancer. 2004;4:937-947.
40. Planchard D,Loriot Y,Besse B.Impact of KRAS in standard treatment of non-small cell lung cancer (NSCLC) patients in 2009: prognostic and predictive value.Bull Cancer. 2009;96:S57-S68.
41. Califano R,Landi L,Cappuzzo F.Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer.Drugs. 2012;72:28-36.
42. Zhang Z,Wang Z.K-ras role in lung cancer therapy.Minerva Chir. 2011;66:251-268.
43. Möller G,Möller E.The concept of immunological surveillance against neoplasia.Transplant Rev. 1976;28:3-16.
44. Hadden JW.Immunodeficiency and cancer: prospects for correction.Int Immunopharmacol. 2003;3:1061-1071.
45. Zitvogel L,Tesniere A,Kroemer G.Cancer despite immunosurveillance: immunoselection and immunosubversion.Nat Rev Immunol. 2006;6:715-727.
46. Tesniere A,Panaretakis T,Kepp O, et al.Molecular characteristics of immunogenic cancer cell death.Cell Death Differ. 2008;15:3-12.
47. Old LJ.Cancer vaccines: an overview.Cancer Immun. 2008;8:1-1.
48. Zitvogel L,Apetoh L,Ghiringhelli F, et al.The anticancer immune response: indispensable for therapeutic success?.J Clin Invest. 2008;118:1991-2001.
49. Ozaki Y,Kontani K,Teramoto K, et al.Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes for use in cancer immunotherapy.Biochem Biophys Res Commun. 2004;317:1089-1095.